Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 20
2003 14
2004 12
2005 14
2006 10
2007 21
2008 16
2009 16
2010 22
2011 30
2012 29
2013 22
2014 28
2015 23
2016 13
2017 15
2018 10
2019 11
2020 19
2021 14
2022 9
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

328 results

Results by year

Filters applied: . Clear all
Page 1
Profile of a Pioneer: E. Donnall Thomas.
Appelbaum FR. Appelbaum FR. Transplant Cell Ther. 2024 Jan;30(1):3-8. doi: 10.1016/j.jtct.2023.12.007. Transplant Cell Ther. 2024. PMID: 38185505 No abstract available.
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Appelbaum FR, Erba HP. Garcia-Manero G, et al. Among authors: appelbaum fr. Leukemia. 2024 Jan;38(1):58-66. doi: 10.1038/s41375-023-02073-x. Epub 2023 Nov 7. Leukemia. 2024. PMID: 37935977 Clinical Trial.
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.
Zarnegar-Lumley S, Alonzo TA, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti A, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogosova-Agadjanyan EL, O'Dwyer K, Tallman MS, Litzow M, Atallah E, Cooper TM, Aplenc RA, Abdel-Wahab O, Gamis AS, Luger S, Erba H, Levine R, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K. Zarnegar-Lumley S, et al. Among authors: appelbaum fr. Blood Adv. 2023 Oct 10;7(19):5941-5953. doi: 10.1182/bloodadvances.2022008282. Blood Adv. 2023. PMID: 37267439 Free PMC article.
Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network.
Termini CM, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Erba HP, Fang M, Lee SC, Naru J, Pogosova-Agadjanyan EL, Radich JP, Willman CL, Wu F, Meshinchi S, Stirewalt DL. Termini CM, et al. Among authors: appelbaum fr. Haematologica. 2023 Nov 1;108(11):3148-3151. doi: 10.3324/haematol.2023.282733. Haematologica. 2023. PMID: 37021537 Free PMC article. No abstract available.
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients.
Pogosova-Agadjanyan EL, Hua X, Othus M, Appelbaum FR, Chauncey TR, Erba HP, Fitzgibbon MP, Jenkins IC, Fang M, Lee SC, Moseley A, Naru J, Radich JP, Smith JL, Willborg BE, Willman CL, Wu F, Meshinchi S, Stirewalt DL. Pogosova-Agadjanyan EL, et al. Among authors: appelbaum fr. Biomark Res. 2023 Mar 16;11(1):31. doi: 10.1186/s40364-023-00461-0. Biomark Res. 2023. PMID: 36927800 Free PMC article.
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study.
Aldoss I, Yin J, Wall A, Mrózek K, Liedtke M, Claxton DF, Foster MC, Appelbaum FR, Erba HP, Litzow MR, Tallman MS, Stone RM, Larson RA, Advani AS, Stock W, Luger SM. Aldoss I, et al. Among authors: appelbaum fr. Blood Adv. 2023 Jan 24;7(2):196-204. doi: 10.1182/bloodadvances.2022007791. Blood Adv. 2023. PMID: 36269846 Free PMC article.
328 results